Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion PANTUMOR-1 phase II study of zongertinib in selected HER2-mutant or HER2-overexpressing/amplified solid tumors
CTR20243544Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zongertinib in Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Started Oct 2024; status: active.
02
Drugs
zongertinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243544.